Brief: New Clinical Data Validates Vor Bio’S Approach Of Using Shielded Transplants
05/09/2024 21:15
Sept 5 (Reuters) - Vor Biopharma Inc VOR.O :
* NEW CLINICAL DATA VALIDATES VOR BIO’S APPROACH OF USING
SHIELDED
TRANSPLANTS TO DELIVER TARGETED THERAPIES
* VOR BIOPHARMA INC: TREM-CEL + MYLOTARG DEMONSTRATED
ENGRAFTMENT,
SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT
* VOR BIOPHARMA INC: VCAR33(ALLO) DEMONSTRATES ENCOURAGING
BIOMARKER DATA AT LOWEST DOSE
* VOR BIOPHARMA: PROGRESSING IND-ENABLING STUDIES TO ENABLE
FUTURE
PHASE 1 STUDIES FOR VADC45
Source text for Eikon: ID:nGNX7Hrc1D
Further company coverage: VOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning